Uniqure NV QURE

NL Biotechnology

$24.51 ▼ -37.33% ($-14.60)

⬇️ Below Yest. Low

Open $23.85

Prev Close $39.11

Day Range $22.47 – $26.00

52W Range $8.73 – $71.50

Market Cap $1.70B

Beta 1.03

EPS (TTM) $-4.05

📋 Company Profile

Industry	Biotechnology
Country	NL
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2014-02-05
Shares Out.	69,370,000
Website	uniqure.com/ ↗
Phone	31202406000
Employees	221
Revenue	$5.8M
Gross Profit	$5.5M
Net Income	-$81.1M
Free Cash Flow	-$161.5M
Total Assets	$985.1M
Total Liabilities	$661.1M
Equity	$324.1M

About Uniqure NV

uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.

Uniqure NV is a publicly traded company under the ticker symbol QURE on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.